Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | IGF2R | P11717 | 4/20 | 0.53 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.53 |
| ▸ | UMPS | P11172 | 5/20 | 0.44 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710624 | 1.00 | FBP1 (0.75) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL18625366 | 1.00 | FBP1 (0.75) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL18625363 | 1.00 | FBP1 (0.75) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL30189347 | 0.86 | FBP1 (1.00) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL20154711 | 0.86 | FBP1 (1.00) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL25083916 | 0.82 | FBP1 (0.70) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL13449624 | 0.82 | FBP1 (0.70) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL13466303 | 0.82 | FBP1 (0.70) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL25084286 | 0.82 | FBP1 (0.70) | FBP1IGF2RAMDHD2UMPSATIC | |
| SCHEMBL4997000 | 0.81 | FBP1 (0.81) | FBP1IGF2RAMDHD2UMPSATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592309-B2 | Positron emission tomography probe to monitor selected sugar metabolism in vivo | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150133777-A1 | POSITRON EMISSION TOMOGRAPHY PROBE TO MONITOR SELECTED SUGAR METABOLISM IN VIVO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133777-A1 | POSITRON EMISSION TOMOGRAPHY PROBE TO MONITOR SELECTED SUGAR METABOLISM IN VIVO | FBP1, DERA, MPI | FBP1 1/4885IGF2R 43/4885AMDHD2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.